Dr. Reddy's Laboratories launches Propofol Injectable Emulsion, USP in the U.S. Market

Deepthi | Myequity news | Date : 24-01-2019 13:05:00 IST

Dr. Reddy's Laboratories Ltd., launched Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of DIPRIVAN (propofol) Injectable Emulsion, USP, approved by the U.S. Food and Drug Administration (USFDA).

The Diprivan brand and generic had U.S. sales of approximately $310 million MAT for the most recent twelve months ending in November 2018 according to IMS Health*.

About Dr. Reddy's:

Dr. Reddy's Laboratories Ltd is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.


More from Myequity